Table 3 Correlations of anti-EBV T cell response upon diagnosis with clinicopathological parameters
From: Cytolytic T-cell response against Epstein-Barr virus in lung cancer patients and healthy subjects
| Â | Â | Anti-EBV T cell responsea | ||
|---|---|---|---|---|
| Â | Â | Yes | No | p-valueb |
Age c | ≤ 65 | 4 (54; 48-63) | 2 (43; 43-59) | 0.294 |
| Â | > 65 | 4 (74; 69-79) | 9 (71; 66-81) | 0.515 |
Histiotype | NSCLC | 5 | 8 | 0.837 |
| Â | SCLC | 3 | 3 | 0.734 |
Sex | M | 5 | 10 | 0.601 |
| Â | F | 3 | 1 | 0.231 |
Performance Status d | 0 | 6 | 10 | 0.782 |
| Â | 1 | 2 | 1 | 0.427 |
Loss of weight | < 5% | 6 | 8 | 0.966 |
|  | ≥ 5% | 2 | 3 | 0.932 |
Stage | I-II | 5 | 5 | 0.684 |
| Â | III-IV | 3 | 6 | 0.657 |
Survival status | Alive | 5 | 6 | 0.657 |
| Â | Dead | 3 | 5 | 0.824 |
Survival | Days | 843.88 ± 235.59 | 757.89 ± 292.30 | 0.512 |